Double-Blind, Randomized, Placebo-Controlled, Crossover, Laboratory Based Study With Rollover Extension to Evaluate Safety of Short-term Use of RE03 in Home Setting in Post-Traumatic Stress Disorder (PTSD) Patients With Sleep Disturbances
Latest Information Update: 08 Oct 2025
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- Acronyms PTSD-PoC
- Sponsors Reconnect Labs
Most Recent Events
- 12 Sep 2025 Status changed from not yet recruiting to recruiting.
- 04 Jul 2025 Planned End Date changed from 1 Jul 2026 to 1 Aug 2026.
- 04 Jul 2025 Planned primary completion date changed from 1 Jun 2026 to 1 Aug 2026.